Obeservational Cohort for Evaluating Future Cardiovascular Disease With High Metabolic Risks

Inclusion Criteria: 1.18 years old ≤ age ≤70 years old; 2. Have ≥1 cardiovascular and metabolic disease: 1. hypertension (systolic blood pressure ≥140mmHg in the resting room and diastolic blood pressure ≥90mmHg in the rest room;Previously diagnosed and taking blood pressure medication); 2. Dyslipidemia: \[LDL-C≥4.1mmol/L and/or HDL-C\<1.0mmol/L and/or TC≥6.2mmol/L and/or TG≥2.3mmol/L\]; 3. fatty liver; 4. Obesity (BMI≥28kg/m2 or waist circumference: male ≥90cm, female ≥85cm); 5. Abnormal glucose metabolism: Impaired fasting blood glucose: fasting blood glucose ≥6.1, \<7.0mmol/L, 2h post-glucose load blood glucose\<7.8mmol/L And/or impaired glucose tolerance: fasting blood glucose\<6.1mmol/L, 2h post-glucose load blood glucose ≥7.8,\<11.1mmol/L and/or HbA1c≥5.7, \<6.5%; 3. Subjects voluntarily participate in the study Exclusion Criteria: 1. Diagnosed type 1 and/or type 2 diabetes; 2. Confirmed history of secondary hypertension (renal parenchymatous hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, coarctation of the aorta, obstructive sleep apnea hypopnea syndrome, etc.); 3. A history of malignant tumors (other than non-metastatic skin basal cell carcinoma or squamous cell carcinoma or cervical cancer in situ that has been appropriately treated or resected); 4. Severe structural heart disease (including valvular heart disease, cardiomyopathy, congenital heart disease); 5. Myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack in the last 6 months; 6. History of cardiovascular and cerebrovascular surgery/interventional treatment (stent, balloon, thrombectomy, etc.); 7. Pregnant women or those who are breastfeeding; 8. Patients with clear immune system abnormalities (systemic lupus erythematosus, etc.); 9. Impaired liver and kidney function (ALT, AST more than 3 times the upper limit of normal, eGFR(CKD-EPI)≤60 mL/min/1.73m2); 10. Patients who cannot follow through on screening.